ym 872 has been researched along with galantamine in 1 studies
| Studies (ym 872) | Trials (ym 872) | Recent Studies (post-2010) (ym 872) | Studies (galantamine) | Trials (galantamine) | Recent Studies (post-2010) (galantamine) |
|---|---|---|---|---|---|
| 41 | 0 | 5 | 1,874 | 209 | 703 |
| Protein | Taxonomy | ym 872 (IC50) | galantamine (IC50) |
|---|---|---|---|
| Chain A, ACETYLCHOLINESTERASE | Tetronarce californica (Pacific electric ray) | 0.652 | |
| Chain A, Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.36 | |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 2.0401 | |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.488 | |
| Cholinesterase | Homo sapiens (human) | 5.4792 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.59 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 2.29 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.8484 | |
| Acetylcholinesterase | Bos taurus (cattle) | 4.53 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 8.3973 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.59 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.59 | |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | 0.8006 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 3.2 | |
| Cholinesterase | Equus caballus (horse) | 7.2215 | |
| Carboxylic ester hydrolase | Equus caballus (horse) | 8.4178 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
1 other study(ies) available for ym 872 and galantamine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |